According to a director of the National Health and Family Planning Commission, 95 % of patented drugs and 95 % of major medical equipment in China are still under patent protection from foreign companies. During the present 5 years plan (“135”), the government has taken steps to speed up drug development by Chinese companies, in particular by funding R&D, by improving the priority review system of CFDA and by revising patent regulations. 2018 is considered an excellent year for Chinese companies to obtain support for submitting original and proprietary new APIs.

China Bio news release, August 31, 2017